A Study on the Adverse Events of the Yellow Fever Vaccine at an International Travelers’ Clinic
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background:Yellow fever (YF) can be prevented through vaccination, but YF vaccination causes adverse events. The increasing number of travelers to YF-endemic areas prompted an investigation of YF vaccination’s adverse events on Koreans. Materials and Methods:From January to December 2007, 318 live-17DD vaccinees at the International Travelers’ Clinic of the National Medical Center were enrolled in this study. Results:The adverse events were evaluated through six telephone interviews of 309 subjects (male: 168, 54.4%) on days 3, 6, 9, 16, 23, and 30 after the administration of the vaccine. There were 106 adverse events in 97 (31.4%) subjects aged 11 months to 70 years (male: 56, 18.1%). Of the 34 (11.0%) subjects who had underlying diseases, 3 (1.0%) reported adverse events (P=0.06). Nineteen (6.1%) of the 72 (23.3%) subjects who concurrently received other vaccines also experienced adverse events (P=0.29). Those who had underlying illnesses and those aged 10 to 19 years reported more frequent adverse events (P=0.06 and 0.14, respectively), but the significance of this finding is uncertain. Most of the adverse events occurred within 10 days after the vaccination and spontaneously subsided. Conclusion:This study shows that most of the YF vaccine’s adverse events are well tolerated and that the vaccine safely protects a vaccinee from YF.
Abstract
Background:Yellow fever (YF) can be prevented through vaccination, but YF vaccination causes adverse events. The increasing number of travelers to YF-endemic areas prompted an investigation of YF vaccination’s adverse events on Koreans. Materials and Methods:From January to December 2007, 318 live-17DD vaccinees at the International Travelers’ Clinic of the National Medical Center were enrolled in this study. Results:The adverse events were evaluated through six telephone interviews of 309 subjects (male: 168, 54.4%) on days 3, 6, 9, 16, 23, and 30 after the administration of the vaccine. There were 106 adverse events in 97 (31.4%) subjects aged 11 months to 70 years (male: 56, 18.1%). Of the 34 (11.0%) subjects who had underlying diseases, 3 (1.0%) reported adverse events (P=0.06). Nineteen (6.1%) of the 72 (23.3%) subjects who concurrently received other vaccines also experienced adverse events (P=0.29). Those who had underlying illnesses and those aged 10 to 19 years reported more frequent adverse events (P=0.06 and 0.14, respectively), but the significance of this finding is uncertain. Most of the adverse events occurred within 10 days after the vaccination and spontaneously subsided. Conclusion:This study shows that most of the YF vaccine’s adverse events are well tolerated and that the vaccine safely protects a vaccinee from YF.
참고문헌 (19)
- Barrett AD, "Yellow fever: a disease that has yet to be conquered", Annu Rev Entomol, 52, pp.209~229 (2007)
- Center for Diseases Control Prevention (CDC), "Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP)", Morbid Mortal Wkly Rep 51(RR17), pp.1~10 (2002)
- Monath TP, "Yellow fever in Vaccines", pp.959~1055 (2008), WB Saunders
- Marfin AA, "Yellow fever and Japanese encephalitis vaccines: indications and complications", Infect Dis Clin North Am, 19, pp.151~168 (2005)
- Barnett ED, "Yellow fever:epidemiology and prevention", Clin Infect Dis, 44, pp.850~856 (2007)
- Monath TP, "Yellow fever: an update", Lancet Infect Dis, 1, pp.11~20 (2001)
- Engel AR, "Charaterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil", Vaccine, 24, pp.2803~2809 (2006)
- Pugachev KV, "New developments in flavivirus vaccines with special attention to yellow fever", Curr Opin Infect Dis, 18, pp.387~394 (2005)
- Camacho LA, "Collaborative group for the study of yellow fever vaccines", Immunogenicity of WHO-17D and brazilian 17DD yellow fever vaccines: a randomized trial, 38, pp.671~678 (2004)
- Pugachev KV, "Heterogenous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing", Vaccine, 25, pp.996~999 (2002)
- Barrett AD, "17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005", Vaccine, 25, pp.2758~2765 (2007)
- Monath TP, "Prevention of yellow fever in persons traveling to the tropics", Clin Infect Dis, 34, pp.1369~1378 (2002)
- Tomori O, "Yellow fever: the recurring plague", Crit Rev Clin Lab Sci, 41, pp.391~427 (2004)
- Martin M, "GeoSentinel Yellow Fever Working Group. Advanced age as a risk factor for illness temporally associated with yellow fever vaccination", Emerg Infect Dis, 7, pp.945~951 (2001)
- Khromova AY, "The Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events", Vaccine, 23, pp.3256~3263 (2005)
- Monath TP, "Yellow fever 17D vaccine safety and immunogenicity in the elderly", Hum Vaccin, 1, pp.207~214 (2005)
- Huntington MK, "The traveling family", Prim Care, 29, pp.1007~1025 (2002)
- World Health Organiztion, "Yellow fever situation in Africa and South America, 2005", Wkly Epidemiol Rec, 81, pp.317~324 (2006)
- Choudri Y, "Review of adverse events reported following use of yellow fever vaccine- Canada, 1987-2000", Can Commun Dis Rep, 28, pp.9~15 (2002)